CN104435040A - Balsamiferou blumea herb and fosfomycin containing compound medicine for livestock and poultry - Google Patents
Balsamiferou blumea herb and fosfomycin containing compound medicine for livestock and poultry Download PDFInfo
- Publication number
- CN104435040A CN104435040A CN201410624502.1A CN201410624502A CN104435040A CN 104435040 A CN104435040 A CN 104435040A CN 201410624502 A CN201410624502 A CN 201410624502A CN 104435040 A CN104435040 A CN 104435040A
- Authority
- CN
- China
- Prior art keywords
- fosfomycin
- compound medicine
- blumea herb
- balsamiferou blumea
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compositae blumea plant, namely balsamiferou blumea herb, and fosfomycin containing compound medicine for livestock and poultry. The compound medicine is prepared from the following raw materials in parts by weight: 3-30 parts of fosfomycin and 5-200 parts of balsamiferou blumea herb. According to the compound medicine, after the balsamiferou blumea herb is added into the fosfomycin, the fosfomycin resistance of bacteria can be reversed, so that the treatment effect of the fosfomycin is improved. By preparing the compound medicine into powder, tablets, oral liquids or granules according to the conventional methods, and feeding in a manner of adding the powder, tablets, oral liquids or granules into livestock and poultry feed according to the ratio of (0.1-7)g: 1kg, the medication cost and drug residue can be greatly reduced, higher economic benefits are created for farmers, and meanwhile, food safety is ensured.
Description
Technical field
The invention belongs to poultry escherichia coli and Salmonella infection treatment technology field, particularly relate to a kind of poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and fosfomycin.
Background technology
Fowl salmonellosis (Avian salmonellosis) is the general name of the poultry disease caused by one or more Salmonellas in Salmonella.Difference according to pathogen antigen structure can be divided into 3 classes: Pullorum Disease, avian typhoid and avian paratyphoid.Wherein Pullorum Disease and avian typhoid Salmonella have host specificity, mainly cause chicken and turkey morbidity; Avian paratyphoid Salmonella then can extensively infect many animals and people, is one of main source of mankind's Salmonella infection and alimentary toxicosis by poultry that it pollutes and products thereof.Fowl salmonellosis often forms quite complicated propagation circulation.Sick fowl and the fowl that carries disease germs are the main sources of infection, by digestive tract, respiratory tract or eye conjunctiva horizontal transmission, poult can be infected after ovum vertical transmission, cause major part dead, poultry carries disease germs for a long time, then the ovum that carries disease germs of output, if hatch in this, as hatching egg, that then can go round and begin again is handed down from age to age, and causes fowl salmonellosis to be difficult to purification in chicken group, causes serious economic loss.Because Salmonella pollutes face greatly in chicken group, and easily produce drug resistance, immune effect of vaccine is in the market all undesirable.Therefore, breeder flock quarantine, medicine control, environment disinfected purifies, strengthen feeding and management and health and epidemic prevention is still control and prevents Salmonella from entering the essential measure of food chain.Chickling drinks 0.01% potassium permanganate solution after going out shell or other drug carries out chemoprophylaxis in 1 ~ 2 day.This bacterium produces drug resistance to common drug, forces in production to have to carry out various medicine and be used alternatingly, in the hope of better controlling fastbacteria.This bacterium produces stronger drug resistance to aminoglycoside medicaments at present, and aminoglycoside inactive enzyme modifies the necessary group of some protection antibacterial activity in these antibacterials molecules, and itself and the ribosomal affinity of target site are greatly reduced.These inactive enzymes comprise aminoglycoside acyltransferase (AAC), aminoglycoside adenylyl transferase (AAD), aminoglycoside phosphotransferase (APH), gland nucleotidyltransferase (ANT) etc.In the fastbacteria of many aminoglycosides, find the inactive enzyme of different qualities at present.
Escherichia coli are common conditioned pathogens, also be the normal a kind of disease sent out, it can formerly have been carried out the coffin upon burial the multiple location severe infections such as chicken acute sepsis, peritonitis, hepatitis, pneumonia, enteritis, also can secondary or mixedly to send out in virosis, causes huge economic loss to aquaculture.The beta-lactam lopps antibiotic such as amoxicillin, ampicillin, ceftiofur, ceftriaxone, amoxicillin/clavulanate, ampicillin/sulbactam are the conventional important drugs of this disease of control, along with cultivation scale intensive degree is more and more large, medication is more and more spread unchecked, its Resistant strain is more and more many, and the report about Drug Resistance of E. coli is also more.Research confirms, one of main mechanism of drug resistance produces beta-lactamase, especially extended spectrumβ-lactamase (Extended-Spectrum β-lactamase, ESBLs), this enzyme can be hydrolyzed beta-lactam nucleus more by force and rapidly, makes this kind of antibiotic lose antibacterial activity.ESBLs is the main enzyme type of beta-lactamase, and it not only to cephalo three generations and aztreonam drug resistance, and is crossing drug resistant to aminoglycoside, quinolones and sulfonamides, only to carbapenems, a mould alkene class medicaments insensitive.Many documents reported colibacillary multi-drug resistant with produce ESBLs have substantial connection, both at home and abroad to comparatively pay close attention to.Inventor has carried out the detection of food animal source pathogenic bacterium ESBLs recently, extraction, enzyme press down the researchs such as enzyme protection effect to antibiotic percent hydrolysis and sulbactam, Tazobactam Sodium and Chinese medicine; show the colibacillary drug sensitive test of part ESBLs, its multidrug resistant rate is apparently higher than non-ESBLs bacterial strain.In addition, result also shows to produce ESBLs bacterial strain not only to the serious drug resistance of the third generation cephalosporins such as ceftiofur, and also to multiple antimicrobial drug drug resistance such as fluoroquinolones, aminoglycoside and sulfonamides, fosfomycin etc., in serious multidrug resistant.Inventor is separated to the escherichia coli of resistance to fosfomycin product fosA3 drug resistant gene producing in ESBLs bacterial strain, more strengthen the drug resistance of antibacterial.
Salmonella and colibacillary drug resistance cause raiser's drug cost to increase, and treatment extends the course for the treatment of, and mortality of livestock increases, and brings larger economic loss, and increase poultry drug residue risk to production.Therefore, the medicine that a kind of Salmonella of the drug resistance to no matter whether and escherichia coli can have better therapeutical effect is needed badly in actual production, and can shorten treatment the course for the treatment of, reduce mortality rate, reduce economic loss and reduce drug residue, for raiser creates higher economic benefit, also ensure that the mankind's is healthy and safe.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and fosfomycin, it can kill antibacterial quickly, overcome large, the residual high and defect that cost is high of weak curative effect that antimicrobial drug treatment causes due to drug resistance problems, consumption, avoid that simple Chinese medicine sterilizing spectrum is narrow, sterilize slow problem.
For solving above technical problem, the present invention by the following technical solutions: a kind of poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and fosfomycin, is made up of the raw material of following weight portion: fosfomycin 3-30 part, Balsamiferou Blumea Herb 5-200 part.
Described compound medicine is prepared into powder, tablet, oral liquid or granule.
The preparation method of described compound medicine is: Balsamiferou Blumea Herb was pulverized 60 mesh sieves, then mixes with pulverous antimicrobial drug, is prepared into powder, tablet, oral liquid or granule according to a conventional method.
For the drug resistance problems that current poultry escherichia coli and Salmonella infection exist, inventor utilizes Chinese medicine Balsamiferou Blumea Herb and antimicrobial drug to form compound medicine.Research proves, after adding Balsamiferou Blumea Herb in antimicrobial drug, can reverse bacterial to the drug resistance of antimicrobial drug, thus improve the therapeutic effect of antimicrobial drug.According to a conventional method this compound medicine is made powder, tablet, oral liquid or granule, add in animal and fowl fodder according to the 0.1-7g principal agent/addition of kg feedstuff and feed, can significantly reduce drug cost and drug residue, for raiser creates higher economic benefit, also ensure that food safety simultaneously.
Detailed description of the invention
One, Balsamiferou Blumea Herb is to the drug resistance inversion Effect study of antimicrobial drug
Antimicrobial drug itself has treatment escherichia coli and the effect of Salmonella, but has stronger drug resistance due to the escherichia coli and Salmonella producing drug resistant gene, causes antimicrobial drug not show good therapeutic effect in normal using dosage situation.
1, Balsamiferou Blumea Herb mix with antimicrobial drug after to colibacillary drug resistance inhibition test
96 orifice plates adopt microtest tube doubling dilution, first determine antimicrobial drug to producing the minimal inhibitory concentration of e. coli strains of ESBLs and fosA3 drug resistant gene and Balsamiferou Blumea Herb to the subinhibitory concentration producing ESBLs and fosA3 drug resistant gene e. coli strains, the Balsamiferou Blumea Herb then adding subinhibitory concentration in the medium reuses microtest tube doubling dilution and cultivates the minimal inhibitory concentration measuring antimicrobial drug; Continuous passage method is utilized to carry out Secondary Culture to product ESBLs and fosA3 drug resistant gene e. coli strains in the culture medium being added with same subinhibitory concentration Balsamiferou Blumea Herb and same concentration antimicrobial drug, until the antimicrobial drug minimal inhibitory concentration observed diminishes more than 4 times compared with before going down to posterity, can be judged as that Balsamiferou Blumea Herb has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 1:
Table 1 subinhibitory concentration (0.5g/mL) Balsamiferou Blumea Herb goes down to posterity and causes the change (μ g/mL) of product ESBLs and fosA3 escherichia coli Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times to the minimal inhibitory concentration of antibiotic-resistance E. coli, can judge that Balsamiferou Blumea Herb has drug resistance inversion effect to product ESBLs and fosA3 drug resistant gene escherichia coli.
2, Balsamiferou Blumea Herb mix with antimicrobial drug after drug resistance inhibition test to Salmonella
96 orifice plates adopt microtest tube doubling dilution, first determine antimicrobial drug to the minimal inhibitory concentration of drug resistance salmonella strain and Balsamiferou Blumea Herb to the subinhibitory concentration of drug resistance salmonella strain, the Balsamiferou Blumea Herb then adding subinhibitory concentration in the medium reuses microtest tube doubling dilution and cultivates the minimal inhibitory concentration measuring antimicrobial drug; Continuous passage method is utilized to carry out Secondary Culture to Salmonella persister in the culture medium being added with same subinhibitory concentration Balsamiferou Blumea Herb and same concentration antimicrobial drug, until the antimicrobial drug minimal inhibitory concentration observed diminishes more than 4 times compared with before going down to posterity, can be judged as that Balsamiferou Blumea Herb has drug resistance inversion effect to antibacterial medical instrument.Result of the test statistics is as shown in table 2:
Table 2 subinhibitory concentration (0.5g/mL) Balsamiferou Blumea Herb goes down to posterity the change (μ g/mL) causing drug resistance Salmonella Western medicine MIC.
As seen from the above table, antimicrobial drug all reduces more than 4 times to the minimal inhibitory concentration of drug resistance Salmonella, can judge that Balsamiferou Blumea Herb has drug resistance inversion effect to drug resistance Salmonella.
Two, the application example of compound medicine of the present invention
Prepare embodiment 1-embodiment 4 according to table 3 formula and following methods: after Balsamiferou Blumea Herb being pulverized 60 mesh sieves, based on raw material, then with pulverous antimicrobial drug by weight ratio put into blender and mix, compound medicine is prepared into formulation products.
The formula of table 3 embodiment 1-4 and preparation dosage form
| Numbering | Antimicrobial drug | Balsamiferou Blumea Herb | Dosage form |
| Embodiment 1 | Fosfomycin 18g | 130g | Powder |
| Embodiment 2 | Fosfomycin 3g | 50g | Tablet |
| Embodiment 3 | Fosfomycin 9g | 10g | Oral liquid |
| Embodiment 4 | Fosfomycin 30g | 170g | Granule |
1, the meat-type duck diarrhoea of compound medicine product to duck field 26, Liuzhou age in days of embodiment 1-4 gained carries out efficacy experiment.
Clinical symptoms: duck group draws watery stools, has obvious indigested feedstuff in feces.The duck appearance foot gradually that indivedual diarrhoea is serious is soft slowly dead.
Cut open inspection pathological changes: the duck that dies of illness dehydration is relatively more serious, indivedual duck is still very large, duck liver enlargement, hyperemia, and adularescent film on the liver of part duck, air bag is muddy, and tentative diagnosis is escherichia coli or duck oromeningitis.
Test therapeutic regimen: morbidity duck group divides six groups of administrations, first group with the addition administration of embodiment 1 according to 0.8g/kg feedstuff, second group with the addition administration of embodiment 2 according to 1.8g/kg feedstuff, 3rd group with the addition administration of embodiment 3 according to 0.2g/kg feedstuff, the 4th group with the addition administration of embodiment 4 according to 0.65g/kg feedstuff; 5th group with the addition administration of fosfomycin powder according to 0.1g/kg feedstuff, the 6th group with the addition administration of the thick powder of Balsamiferou Blumea Herb according to 4g/kg feedstuff; Above six groups of therapeutic regimens all continue use 5 days.
Result of use is fed back: first group to the 4th group medication is after 3 days, and sick duck no longer draws watery stools, formed stools, no longer occurs dead duck, and continue use 2 days, duck group be almost recovered; 5th group of medication is after 3 days, duck group DeGrain, much still draw watery stools, containing indigested feedstuff, continue use 2 days, some takes a turn for the better a little, but not good thorough, rare watery stools still occurs, raiser uses the compound medicine of embodiment 1 gained instead, continue use 3 days, feces all transfers to normally; 6th group of medication is after 3 days, and duck does not have too large remarkable improvement, and continue use 2 days, the duck phenomena of mortality are not still effectively controlled.Visible, the compound medicine containing Balsamiferou Blumea Herb is better than folk prescription to the curative effect that duck is suffered from diarrhoea.
2, embodiment 1-4 gained compound medicine product is to the efficacy experiment of Salmonella gallinarum disease.
Clinical symptoms: Guigang, Guangxi chicken house, 13 age in days laying hens, there is dysentery in chicken group, row's white, pasty state loose stool, and perianal tomentum fecal pollution, has Calx sample lump, and what have sends painful shriek, has the phenomena of mortality.Cut open the indivedual Hepar Gallus domesticus enlargement of inspection be kermesinus to darkviolet, or slightly khaki, matter is crisp easily broken, and surface is dispersed in or greyish white, the downright bad point of lark that gathers, and is the petechia of redness sometimes, typical Salmonella genius morbi.
Laboratory diagnosis: get pathologic liver dye sheet, Gram’s staining, basis of microscopic observation, the gram negative bacilli of red color visible; Tentatively be judged as Salmonella disease.Cultivated by Salmonella, biochemical test is differentiated, judge that chicken infects as Salmonella disease, drug sensitive test result is judged as persister Salmonella according to NCCLS standard.
Test therapeutic regimen: morbidity chicken group is divided into 6 groups of administrations, first group with the addition administration of embodiment 1 according to 0.8g/kg feedstuff, second group with the addition administration of embodiment 2 according to 1.8g/kg feedstuff, 3rd group with the addition administration of embodiment 3 according to 0.2g/kg feedstuff, the 4th group with the addition administration of embodiment 4 according to 0.65g/kg feedstuff; 5th group with the addition administration of fosfomycin powder according to 0.1g/kg feedstuff, the 6th group with the addition administration of the thick powder of Balsamiferou Blumea Herb according to 4g/kg feedstuff; Above six groups of therapeutic regimens all continue use 5 days.
Staining effect: after the chicken group medication of first group to the 4th group, sick chicken feed intake rises, and no longer occurs dead chicken, and continue use 3 days, chicken group be almost recovered; The chicken group medication of the 5th group is after 2 days, and chicken group majority is still unhealthy, still has indivedual chicken death, and continue use 3 days, chicken death phenomenon is not still effectively controlled; The chicken group medication of the 6th group is after 2 days, and chicken group does not have too large remarkable improvement, and continue use 3 days, chicken death phenomenon is not still effectively controlled.Visible, the compound medicine curative effect containing Balsamiferou Blumea Herb is better than folk prescription.
Claims (2)
1. contain a poultry compound medicine for Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and fosfomycin, it is characterized in that, be made up of the raw material of following weight portion: fosfomycin 3-30 part, Balsamiferou Blumea Herb 5-200 part.
2. the poultry compound medicine containing Compositae Herba Blumeae Balsamiferae platymiscium Balsamiferou Blumea Herb and fosfomycin according to claim 1, it is characterized in that, described compound medicine is prepared into powder, tablet, oral liquid or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410624502.1A CN104435040A (en) | 2014-11-07 | 2014-11-07 | Balsamiferou blumea herb and fosfomycin containing compound medicine for livestock and poultry |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410624502.1A CN104435040A (en) | 2014-11-07 | 2014-11-07 | Balsamiferou blumea herb and fosfomycin containing compound medicine for livestock and poultry |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104435040A true CN104435040A (en) | 2015-03-25 |
Family
ID=52882302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410624502.1A Pending CN104435040A (en) | 2014-11-07 | 2014-11-07 | Balsamiferou blumea herb and fosfomycin containing compound medicine for livestock and poultry |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104435040A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106166176A (en) * | 2016-08-22 | 2016-11-30 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and fosfomycin |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933085A (en) * | 2014-04-25 | 2014-07-23 | 广西大学 | Method for treating Escherichia coli infection diseases by using creat and fosfomycin |
| CN103948656A (en) * | 2014-04-25 | 2014-07-30 | 广西大学 | Creat/fosfomycin-containing compound medicine for livestock and fowl |
-
2014
- 2014-11-07 CN CN201410624502.1A patent/CN104435040A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103933085A (en) * | 2014-04-25 | 2014-07-23 | 广西大学 | Method for treating Escherichia coli infection diseases by using creat and fosfomycin |
| CN103948656A (en) * | 2014-04-25 | 2014-07-30 | 广西大学 | Creat/fosfomycin-containing compound medicine for livestock and fowl |
Non-Patent Citations (2)
| Title |
|---|
| 梁启成等: "《中国壮药学》", 31 May 2005, 广西民族出版社 * |
| 郭小清等: "穿心莲的药理作用及其在兽医临床上的应用进展", 《中国动物保健》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106166176A (en) * | 2016-08-22 | 2016-11-30 | 广西大学 | A kind of poultry compound medicine containing Cortex Cinnamomi and fosfomycin |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103989728B (en) | It is a kind of to contain the livestock and poultry compound medicine containing pearl grass and beta-lactam class antimicrobial | |
| CN103948930B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and beta-lactam antimicrobial drug | |
| CN103977090B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and florfenicol | |
| CN103961421A (en) | Compound medicine containing radix paeoniae rubra and mequindox for livestock and poultry | |
| CN103989725A (en) | Acalypha australis L. and amikacin containing compound medicine for livestock and poultry | |
| CN103977089B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and fosfomycin | |
| CN103690952A (en) | Compound drug for treating livestock and poultry escherichia coli infected diseases | |
| CN103933086A (en) | Creat/amikacin-containing compound medicine for livestock and fowl | |
| CN103989729A (en) | Acalypha australis L. and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989731A (en) | Acalypha australis L. and florfenicol containing compound medicine for livestock and poultry | |
| CN103989727A (en) | Acalypha australis L. and mequindox containing compound medicine for livestock and poultry | |
| CN103948691B (en) | A kind of poultry compound medicine containing Radix Paeoniae Rubra and sulfamonomethoxine sodium | |
| CN103948692B (en) | A kind of livestock and poultry compound medicine containing the radix paeoniae rubrathe and amikacin | |
| CN104306420A (en) | Balsamiferou blumea herb and sulfamonomethoxine sodium containing compound medicine for livestock and poultry | |
| CN103989726A (en) | Acalypha australis L. and fosfomycin containing compound medicine for livestock and poultry | |
| CN103948656A (en) | Creat/fosfomycin-containing compound medicine for livestock and fowl | |
| CN103977088A (en) | Compound medicine containing radix paeoniae rubrathe and fluoroquinolones antibacterial drug used for livestock and poultry | |
| CN104337847B (en) | A kind of livestock and poultry compound medicine containing phoenix-tail fern and phosphonomycin | |
| CN104435012A (en) | Pteris multifida and florfenicol-containing compound drug for livestock and poultry | |
| CN104367601A (en) | Compound medicine containing herba pteridis multifidae and mequindox for livestock and poultry | |
| CN103933543A (en) | Method for treating Escherichia coli infection diseases by using creat and colimycin | |
| CN103933544A (en) | Creat/colimycin-containing compound medicine for livestock and fowl | |
| CN104306422A (en) | Balsamiferou Blumea herb and beta-lactam antibacterial drug containing compound medicine for livestock and poultry | |
| CN104435038A (en) | Balsamiferou blumea herb and mequindox containing compound medicine for livestock and poultry | |
| CN104435013A (en) | Pteris multifida and amikacin-containing compound drug for livestock and poultry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150325 |
|
| RJ01 | Rejection of invention patent application after publication |